VZV gI Antibodies

Santa Cruz Biotechnology offers a broad range of VZV gI monoclonal antibodies for research focused on understanding the varicella-zoster virus (VZV) and its associated pathologies. VZV gI monoclonal antibodies are compatible with multiple experimental techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). The VZV gI protein plays a crucial role in the virus's ability to evade the host immune response and is essential for viral entry into host cells. Understanding the function of VZV gI is vital for developing therapeutic strategies against VZV-related diseases, such as chickenpox and shingles. By studying VZV gI, researchers can gain insights into viral pathogenesis and potential vaccine targets. VZV gI research has significant implications for understanding viral transmission and infection mechanisms. Current investigations focus on how VZV gI facilitates virus-host cell interactions and membrane fusion processes. Ongoing studies of VZV gI continue to reveal new aspects of viral biology and potential therapeutic approaches. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing our understanding of viral infections and developing effective treatments for VZV-related diseases.